Wang Hao, Guo Weihong, Hu Yanfeng, Mou Tingyu, Zhao Liying, Chen Hao, Lin Tian, Li Tuanjie, Yu Jiang, Liu Hao, Li Guoxin
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Mol Clin Oncol. 2018 Oct;9(4):423-431. doi: 10.3892/mco.2018.1683. Epub 2018 Jul 26.
The present study was performed to evaluate the predictive capacity of the 8th edition vs. the 7th edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system for overall survival (OS) of patients with gastric cancer. Data of eligible patients with gastric cancer in our institution between June 2004 and June 2014 were retrospectively reviewed. A total of 1,506 patients were followed up to July 2016, among whom 1,484 patients with complete stage information were included in the TNM staging analysis. A total of 339 (22.8%) patients presented stage migration, including 325 (21.9%) migrating to a lower tier and 14 (0.9%) to a higher tier. All patients with stage migration to a lower tier were in stage III, including 177 (54.5%) patients migrating from stage IIIB to IIIA, and 148 (45.5%) from stage IIIC to IIIB. Patients migrating from IIIB to IIIA yielded a median OS time and 5-year OS rate closer to those remaining in stage IIIA. Similarly, patients migrating from IIIC to IIIB yielded a median OS time and 5-year OS rate closer to those remaining in stage IIIB. The 7th edition of the staging system exhibited prognostic discrepancy in discriminating stage IIIA from IIIB on survival curves, which was improved in the 8th edition. The 8th edition had a better predictive capability of survival, as evidenced by a smaller value of -2log likelihood in the Cox proportional regression model (7th edition 4738.859 vs. 8th edition 4736.683). Therefore, the present study demonstrated that the 8th edition of the AJCC TNM staging system is superior to the 7th edition in predicting the OS of patients with gastric cancer.
本研究旨在评估美国癌症联合委员会(AJCC)肿瘤-淋巴结-转移(TNM)分期系统第8版与第7版对胃癌患者总生存期(OS)的预测能力。回顾性分析了2004年6月至2014年6月间我院符合条件的胃癌患者数据。共有1506例患者随访至2016年7月,其中1484例具有完整分期信息的患者纳入TNM分期分析。共有339例(22.8%)患者出现分期迁移,其中325例(21.9%)迁移至较低分期,14例(0.9%)迁移至较高分期。所有分期迁移至较低分期的患者均为Ⅲ期,其中177例(54.5%)从ⅢB期迁移至ⅢA期,148例(45.5%)从ⅡIC期迁移至ⅢB期。从ⅢB期迁移至ⅢA期的患者中位总生存期和5年总生存率更接近ⅢA期未迁移患者。同样,从ⅡIC期迁移至ⅢB期的患者中位总生存期和5年总生存率更接近ⅢB期未迁移患者。第7版分期系统在生存曲线上区分ⅢA期和ⅢB期时存在预后差异,第8版有所改善。第8版具有更好的生存预测能力,Cox比例回归模型中-2log似然值更小(第7版4738.859 vs.第8版4736.683)。因此,本研究表明AJCC TNM分期系统第8版在预测胃癌患者总生存期方面优于第7版。